Alzheimer's Disease Clinical Trial
— cuiDemOfficial title:
Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres
An experimental study designed to test the effectiveness of a psychological intervention based on group therapy for the caregivers of Alzheimer's disease patients. The intervention consists of 16 sessions of a cognitive-behavioral psychological group therapy. This study aims to demonstrate that Alzheimer's patients' caregivers can decrease the feelings of burden after been involved in a group therapy.
| Status | Completed |
| Enrollment | 231 |
| Est. completion date | September 2015 |
| Est. primary completion date | July 2014 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Main caregiver of an Alzheimer Disease Patient. - Alzheimer Disease Patient with mild/severe cognitive impairment. - High compliance to therapy sessions. - Sign informed consent. Exclusion Criteria: - Low commitment to develop all study phases. - Caregiver activity remunerated. - Caregiver with psychiatric disorders that can affect the development of the sessions. - Caregivers who have received psychological care during last year. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Spain | AFA Barcelona | Barcelona | |
| Spain | Centro de día Vitalia | Barcelona | |
| Spain | AFA Burgos | Burgos | |
| Spain | AFA Castellón | Castellón | |
| Spain | AGUAFA | Guadasuar | |
| Spain | AFA Lleida | Lleida | |
| Spain | Centro de envejecimiento saludable | Málaga | |
| Spain | Fundació Ana Ribot | Pallejà | |
| Spain | AVAN | Sabadell | |
| Spain | AFATE | Tenerife | |
| Spain | AFA Terres de l'Ebre | Tortosa |
| Lead Sponsor | Collaborator |
|---|---|
| Barcelonabeta Brain Research Center, Pasqual Maragall Foundation |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Efficacy of group therapy in caregiver burden measured by Zarit Burden Interview. | 16 months | No | |
| Secondary | Change in caregiver burden from baseline compared to the control and active arms measured by Zarit Burden Interview. | 4 months and 16 months | No | |
| Secondary | Change in anxiety and depression from baseline compared to the control and active arms measured by Goldberg Scale. | 4 months and 16 months | No | |
| Secondary | Descriptive analysis of the caregivers' characteristics (sociodemographics, relation wih the AD patient). | Baseline (0 months) | No | |
| Secondary | Descriptive analysis of the caregiver's cognition using DEM-DETECT Module 1. | 4 months | No | |
| Secondary | Preliminary cost-effectiveness analysis related resources needed to caregivers and Alzheimer patients. | 4 months - 16 months | No | |
| Secondary | Change in quality of life from baseline compared to the control and active arms measured by Casp-19 and SF-36 questionnaires. | 4 months - 16 months | No | |
| Secondary | Change in resilience from baseline compared to the control and active arms measured by Connor-Davidson Resilience Scale. | 4 months - 16 months | No | |
| Secondary | Change in functional social support from baseline compared to the control and active arms using Duke-UNC questionnaire. | 4 months - 16 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
| Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
| Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
| Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
| Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
| Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
| Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
| Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
| Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
| Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
| Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
| Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
| Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
| Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
| Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
| Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
| Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
| Completed |
NCT02094729 -
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |